Startups channel feed

Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Last year
Financing

Or­bital Ther­a­peu­tics clos­es South San Fran­cis­co lab, elim­i­nat­ing some roles

Last year
People

Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Last year
Financing

UCB, Eli Lil­ly-backed Via­Nautis rais­es $25M in Se­ries A to de­vel­op ge­net­ic nanomed­i­cines

Last year
Financing

CAR­GO's $281M IPO could be the last list­ing of 2023 af­ter mar­ket's 'dras­tic turn'

Last year
Financing
Cell/Gene Tx

For­ward Ther­a­peu­tics, the first biotech from Curie.Bio, rais­es $50M for oral small mol­e­cules in im­munol­o­gy

Last year
Financing

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Last year
Cell/Gene Tx

Flag­ship Pi­o­neer­ing takes an­oth­er big step across the globe, plant­i­ng its biotech flag in Asia

Last year
Financing
Bioregnum

Lil­ly backs Or­so­Bio's $60M Se­ries A for PhII tri­als in obe­si­ty and NASH

Last year
Financing
Pharma

Ex­clu­sive: With back­ing of Ravens own­er, Black­bird launch­es with $100M to boost Bal­ti­more’s biotech scene

Last year
Financing

Dutch-US biotech rais­es $61M to test ex-Mit­subishi Tan­abe drug for schiz­o­phre­nia

Last year
Financing
Deals

CAR­GO Ther­a­peu­tics eyes one of 2023's largest IPOs in a dull year for list­ings

Last year
Financing
Cell/Gene Tx

Bris­tol My­ers buys Orum Ther­a­peu­tic­s' pro­tein de­grad­er take on AD­Cs for $100M up­front

Last year
Deals
Pharma

Lex­eo Ther­a­peu­tics joins small class of 2023 biotech IPOs in $100M Nas­daq list­ing

Last year
Financing
Cell/Gene Tx

Or­biMed and Third Rock’s Ter­re­mo­to Bio­sciences rais­es $175M for small mol­e­cule R&D

Last year
Financing

Gene ther­a­py biotech Lo­can­abio to shut­ter by year’s end

Last year
People
Cell/Gene Tx

‘Small mol­e­cules are sexy again’: Gate Bio­science de­buts with $60M and a new way to stop dis­ease-caus­ing pro­teins

Last year
Financing

Cana­di­an gene ther­a­py biotech en­Gene starts trad­ing on Nas­daq af­ter com­plet­ing For­bion SPAC deal

Last year
Financing
Cell/Gene Tx

Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: Trail­ing Karuna, Map­Light Ther­a­peu­tics aims to im­prove schiz­o­phre­nia, CNS drugs with $225M Se­ries C

Last year
Financing

Man­aT Bio, a KRAS biotech from Bert Vo­gel­stein and Catalio, tar­gets $153M with Third Rock part­ner as CEO

Last year
Financing

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

Last year
Financing
Cell/Gene Tx

Aio­los Bio launch­es with $245M Se­ries A, chas­ing one of asth­ma’s hottest tar­gets

Last year
Financing

CAR­GO Ther­a­peu­tics heads to Nas­daq in first CAR-T cell ther­a­py IPO pitch of 2023

Last year
Financing
Cell/Gene Tx
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times